Amid ongoing controversy over a federal drug discount program for safety-net hospitals, a new survey finds a dozen state Medicaid programs rely on an arguably inadequate method to avoid receiving duplicate rebates, which could provide a boost for taxpayers but hurt the pharmaceutical industry’s bottom line.

At issue is the interplay between Medicaid and the so-called 340B program, which was created in 1992 and requires drug makers to offer discounts of up to 50% on all outpatient drugs — for everything from AIDS to diabetes — to hospitals and clinics that serve indigent populations. There are approximately 12,400 so-called covered entities participating in the program, according to the U.S. Human Resources and Services Administration.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy